Along similar lines, disruption of the CD47-SIRPα axis has been shown to synergize with the Fc-mediated pro-phagocytic stimulus of a mAb targeting a tumor antigen, such as rituximab, an antiCD20 mAb [12]. Here, CD47 is linked to neoplasm.